|
Gene: SLC10A3 |
Gene summary for SLC10A3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC10A3 | Gene ID | 8273 |
Gene name | solute carrier family 10 member 3 | |
Gene Alias | DXS253E | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P09131 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8273 | SLC10A3 | LZE20T | Human | Esophagus | ESCC | 2.29e-08 | 3.80e-01 | 0.0662 |
8273 | SLC10A3 | LZE24T | Human | Esophagus | ESCC | 1.31e-40 | 1.19e+00 | 0.0596 |
8273 | SLC10A3 | LZE21T | Human | Esophagus | ESCC | 4.03e-06 | 4.15e-01 | 0.0655 |
8273 | SLC10A3 | P1T-E | Human | Esophagus | ESCC | 1.88e-17 | 1.10e+00 | 0.0875 |
8273 | SLC10A3 | P2T-E | Human | Esophagus | ESCC | 1.98e-37 | 6.24e-01 | 0.1177 |
8273 | SLC10A3 | P4T-E | Human | Esophagus | ESCC | 4.38e-26 | 7.50e-01 | 0.1323 |
8273 | SLC10A3 | P5T-E | Human | Esophagus | ESCC | 7.55e-14 | 3.34e-01 | 0.1327 |
8273 | SLC10A3 | P8T-E | Human | Esophagus | ESCC | 6.68e-46 | 8.45e-01 | 0.0889 |
8273 | SLC10A3 | P9T-E | Human | Esophagus | ESCC | 1.86e-25 | 7.08e-01 | 0.1131 |
8273 | SLC10A3 | P10T-E | Human | Esophagus | ESCC | 1.96e-31 | 6.34e-01 | 0.116 |
8273 | SLC10A3 | P11T-E | Human | Esophagus | ESCC | 1.11e-26 | 1.12e+00 | 0.1426 |
8273 | SLC10A3 | P12T-E | Human | Esophagus | ESCC | 5.11e-53 | 9.89e-01 | 0.1122 |
8273 | SLC10A3 | P15T-E | Human | Esophagus | ESCC | 1.02e-11 | 3.59e-01 | 0.1149 |
8273 | SLC10A3 | P16T-E | Human | Esophagus | ESCC | 5.08e-13 | 1.94e-01 | 0.1153 |
8273 | SLC10A3 | P17T-E | Human | Esophagus | ESCC | 1.95e-08 | 4.73e-01 | 0.1278 |
8273 | SLC10A3 | P19T-E | Human | Esophagus | ESCC | 2.36e-15 | 1.24e+00 | 0.1662 |
8273 | SLC10A3 | P20T-E | Human | Esophagus | ESCC | 1.83e-19 | 4.72e-01 | 0.1124 |
8273 | SLC10A3 | P21T-E | Human | Esophagus | ESCC | 3.87e-47 | 1.02e+00 | 0.1617 |
8273 | SLC10A3 | P22T-E | Human | Esophagus | ESCC | 2.64e-51 | 9.27e-01 | 0.1236 |
8273 | SLC10A3 | P23T-E | Human | Esophagus | ESCC | 1.13e-54 | 1.44e+00 | 0.108 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | |
Stomach | GC | |
Stomach | CAG with IM | |
Stomach | CSG | |
Stomach | CAG |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00325261 | Esophagus | ESCC | response to retinoic acid | 63/8552 | 107/18723 | 4.05e-03 | 1.62e-02 | 63 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
GO:0032526 | Oral cavity | OSCC | response to retinoic acid | 54/7305 | 107/18723 | 1.04e-02 | 3.54e-02 | 54 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC10A3 | SNV | Missense_Mutation | c.1337N>A | p.Ser446Tyr | p.S446Y | P09131 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
SLC10A3 | SNV | Missense_Mutation | novel | c.808N>G | p.Ser270Gly | p.S270G | P09131 | protein_coding | tolerated(1) | benign(0.015) | TCGA-A7-A13G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD |
SLC10A3 | SNV | Missense_Mutation | c.1272N>T | p.Gln424His | p.Q424H | P09131 | protein_coding | deleterious(0.02) | possibly_damaging(0.473) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
SLC10A3 | SNV | Missense_Mutation | novel | c.77T>C | p.Leu26Ser | p.L26S | P09131 | protein_coding | tolerated_low_confidence(0.15) | benign(0.003) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC10A3 | SNV | Missense_Mutation | c.1366N>A | p.Gly456Ser | p.G456S | P09131 | protein_coding | tolerated(1) | benign(0.052) | TCGA-E2-A15A-06 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
SLC10A3 | SNV | Missense_Mutation | rs138863812 | c.544N>A | p.Ala182Thr | p.A182T | P09131 | protein_coding | tolerated(0.62) | benign(0) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
SLC10A3 | SNV | Missense_Mutation | c.1196N>C | p.Val399Ala | p.V399A | P09131 | protein_coding | tolerated(0.07) | benign(0.065) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC10A3 | SNV | Missense_Mutation | c.302N>T | p.Pro101Leu | p.P101L | P09131 | protein_coding | tolerated(0.82) | benign(0) | TCGA-Q1-A5R1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC10A3 | SNV | Missense_Mutation | rs371811548 | c.1096N>A | p.Gly366Ser | p.G366S | P09131 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CM-6678-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
SLC10A3 | SNV | Missense_Mutation | c.354G>T | p.Lys118Asn | p.K118N | P09131 | protein_coding | tolerated(0.4) | benign(0.255) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |